DeepQure has announced progress of clinical trials of its extravascular renal denervation device, HyperQure.
The company is actively conducting clinical trials in both South Korea and the USA, which it says demonstrate “promising” results. In South Korea, seven patients have undergone the procedure, showing meaningful reductions in blood pressure without any adverse events during- or post-operation. The company aims to complete enrolment for its Korean clinical trial within the first quarter of 2025.
In the USA, DeepQure successfully completed its first clinical case on 17 January 2025, at the University of California, Irvine (UC Irvine). The procedure, performed by Pengbo Jiang, yielded significant blood pressure reductions one month after the operation with no reported complications. The next patient is scheduled for treatment in March, with additional institutional review board (IRB) approvals secured from institutions including Mayo Clinic and Stanford University.
DeepQure’s US clinical trial spans six university hospitals, with IRB approvals finalised. The company plans to enrol 15 patients in the first half of 2025, with the ultimate goal of initiating a pivotal study by year-end to establish the safety and efficacy of HyperQure.
Beyond hypertension, DeepQure is expanding its technology to address atrial fibrillation (AF), one of the most common cardiac arrhythmias. The company has submitted an application to South Korea’s Ministry of Food and Drug Safety (MFDS) to initiate clinical trials for AF treatment.
Currently, pulmonary vein isolation (PVI) is the standard treatment for AF, but its major drawback is a high recurrence rate. DeepQure’s renal denervation technology is expected to enhance the effectiveness of PVI procedures by reducing recurrence rates, offering a breakthrough solution in a field where drug therapy has shown limited success.
